Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck’s Anti-PCSK9 Pill Sets Up Convenience Battle Against Infrequently Dosed Injectables

25 Aug 2023

• By Alaric DeArment

Merck announced the initiation of its Phase III program for oral PCSK9 inhibitor MK-0616 • Source: Shutterstock

Related Content

Two Cardiovascular Trial Hits Get Merck & Co.’s Blood Pumping

08 Mar 2023

Merck & Co.’s Big Ambition To ‘Democratize’ PCSK9s

07 Mar 2023

Can Sanofi Catch Up With Amgen Now That Praluent Has CV Risk-Reduction Claim?

29 Apr 2019

Related Companies

Merck & Co., Inc.

Amgen, Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Novartis AG

Gilead Sciences, Inc.

ViiV Healthcare

GSK plc

Pfizer Inc.

Shionogi & Co. Ltd.

Esperion Therapeutics, Inc.

Additional Topics

Clinical Trials Business Strategies Research & Development Cardiovascular BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.